ArticleResearch square2024
Concurrent TB and HIV therapies effectively control clinical reactivation of TB during co-infection but fail to eliminate chronic immune activation.
Riti Sharan, Yi Zou, Zhao Lai, Bindu Singh, Vinay Shivanna, Edward Dick, Shannan Hall-Ursone, Shabaana Khader, Smriti Mehra, Xavier Alvarez and 2 more
Abstract readPreprint
In one paragraphArticle in Research square, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
12 authors.
Riti SharanTexas Biomedical Research Institute.
Yi ZouUTHSCSA.
Zhao LaiThe University of Texas Health San Antonio.
Bindu SinghTexas Biomedical Research Institute.
Vinay ShivannaTexas Biomedical Research Institute.
Edward DickSouthwest National Primate Research Center.
Shannan Hall-UrsoneTexas Biomedical Research Institute.
Smriti MehraTexas Biomedical Research Institute.
Xavier AlvarezTexas Biomedical Research Institute.
Funding
The Southwest National Primate Research Center Supplement- Infrastructure improvements of ABSL2 holding areasP51OD011133 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Larry S. Schlesinger · 2012 to 2026
$129.7MTISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Lei Zheng · 1991 to 2026
$59.1MViral Testing CoreU42OD010442 · OD · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI Smriti Mehra · 2012 to 2026
$35.6MTexas Developmental Center for AIDS ResearchP30AI161943 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI GIORDANO, THOMAS P · 2021 to 2025
$8.3MInterdisciplinary NexGen TB research Advancement Center (IN-TRAC)P30AI168439 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI JOANNE TURNER · 2022 to 2026
$6.9MEmory/Georgia TB Research Advancement Center (TRAC)P30AI168386 · NIAID · EMORY UNIVERSITY · PI Jeffrey M Collins · 2022 to 2026
$5.8MPerturbation of antigen-specific T cell responses in latent TB/SIV co-infectionR01AI111943 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KAUSHAL, DEEPAK, RENGARAJAN, JYOTHI · 2015 to 2019
$3.9MImpact of concurrent HIV and latent TB therapies on Mtb-specific immune function-Diversity SupplementR01AI123047 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI KAUSHAL, DEEPAK, RENGARAJAN, JYOTHI · 2017 to 2020
$3.9MAdvancing Cancer Research Through Next Generation Sequencing at Mays Cancer Center of UT Health San AntonioR50CA265339 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Zhao Lai · 2022 to 2026
$957kSingle cell trancriptomics to identify LTBI reactivation markers in TB/HIV co-infectionR21AI170148 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI SHARAN, RITI · 2022 to 2023
$800kEffect of IL-21 treatment concurrent to ART and 3HP in Mtb/SIV co-infectionR56AI184089 · NIAID · TEXAS BIOMEDICAL RESEARCH INSTITUTE · PI SHARAN, RITI · 2024 to 2024
$719kIllumina NovaSeq 6000 Sequencing SystemS10OD030311 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LAI, ZHAO · 2021 to 2021
$600kNCI NIH HHS P30 CA054174NCI NIH HHS R50 CA265339NIAID NIH HHS P30 AI161943NIAID NIH HHS P30 AI168386NIAID NIH HHS P30 AI168439NIAID NIH HHS R01 AI111943NIAID NIH HHS R01 AI123047NIAID NIH HHS R21 AI170148NIAID NIH HHS R56 AI184089NIH HHS K01 OD031898NIH HHS P51 OD011133NIH HHS S10 OD028732NIH HHS S10 OD030311NIH HHS S10 OD032443NIH HHS U42 OD010442
6 · The paper itselfAbstract
The majority of Human Immunodeficiency Virus (HIV) negative individuals exposed to
Indexed as
3HPcARTLTBIreactivationTB/SIV co-infection
Identifiers
PMID39257997
PMCPMC11384027
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390